PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice

Anthony R. Mato, MD, MSCE - Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care

Prof. Dr. med. Stephan Stilgenbauer - New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management

Stuart S. Winter, MD - Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

Zev A. Wainberg, MD - Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity

James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice

Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

Gail J. Roboz, MD - The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care

David P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease

Michael R. Bishop, MD - CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma

Stephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care

Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

Nasser Altorki, MD - How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

Jonathan Corren, MD - Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma

Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC

Joe R. Anderson, PharmD, PhC - Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care

Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice

Nina Shah, MD - Mapping the Therapeutic Odyssey in Multiple Myeloma: Interprofessional Guidance on Evidence-Based Treatment Selection and Sequencing

Michael E. Wechsler, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients With Uncontrolled, Moderate to Severe Asthma: Comparing Approaches With Experts Around the World

Milind Desai, MD, MBA - New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy: Analysis From Washington, DC

Anthony R. Mato, MD, MSCE - Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency

Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

Geoffrey Barnes, MD, MSc - Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention

Gregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Exper

John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs

Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC - Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?

Purvi S. Parikh, MD, FACP, FACAAI / Cedric ""Jamie"" Rutland, MD - Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

Stephen V. Liu, MD - Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors

Boris Sepesi, MD / Tina Cascone, MD, PhD - Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do

Paneez Khoury - Easing the Burden of Hypereosinophilic Syndrome: An Animated Exploration of the Role of Targeted Therapy to Improve Patient Outcomes

Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care

Biree Andemariam, MD - The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities

Lorinda Chung, MD, MS - Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities

Nathan H. Fowler, MD - A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care

Neal K. Lakdawala, MD - Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment

Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multi

John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management

Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers

David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC

Javid Moslehi, MD - Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?

Lynette M. Sholl, MD - Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings

Jonathan W. Goldman, MD - Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team

Peter A. Kouides, MD - Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care With Current and Emerging Management Strategies

Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics

Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC